Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF
Status:
Completed
Trial end date:
2017-01-31
Target enrollment:
Participant gender:
Summary
This is a phase IV, twelve week, open label, randomized, parallel group study to assess
safety and tolerability of combined treatment with nintedanib and pirfenidone.
A secondary objective is to assess the exposure based on PK trough concentration values to
nintedanib either given alone or in combination with pirfenidone and to assess the exposure
of pirfenidone when combined with nintedanib.